A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer. [electronic resource]
Producer: 20171204Description: 15948-58 p. digitalISSN:- 1949-2553
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Binding Sites
- Biomarkers, Tumor -- analysis
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cisplatin -- therapeutic use
- Female
- Gene Expression Regulation, Neoplastic -- genetics
- Genotype
- Humans
- Kaplan-Meier Estimate
- Lung Neoplasms -- drug therapy
- Male
- MicroRNAs -- genetics
- Middle Aged
- Paclitaxel -- therapeutic use
- Polymorphism, Single Nucleotide
- Proto-Oncogene Protein c-ets-2 -- genetics
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.